Zobrazeno 1 - 10
of 29
pro vyhledávání: '"S Deplacido"'
Autor:
L. Panico, Alessandro Morabito, A Martignetti, Alfredo Marinelli, S Deplacido, Guido Pettinato, Rossella Lauria, Chiara Carlomagno, G. Petrella, M Delaurentiis, Ar Bianco, Ciro Gallo, F. Perrone
Publikováno v:
Oncology reports. 1(6)
The impact of multicentricity in primary breast cancer on relapse or death after radical or modified radical mastectomy was evaluated in 1336 consecutive patients. Multiple tumor foci were found in 11.7% of breast cancers: in 8.4% multicentricity was
Autor:
Fortunato Ciardiello, Giampaolo Tortora, S Deplacido, M Delaurentiis, Ar Bianco, Pierosandro Tagliaferri, Elide Matano, Alessandro Morabito, Michele Caraglia, Montesarchio, Giovannella Palmieri, M. Famiani, A Rea
Publikováno v:
Europe PubMed Central
The antitumor activity and toxicity profile of a new therapeutic combination was investigated for patients with non-Hodgkin's lymphoma (NHL). The regimen consisted of mitoxantrone (10 mg/m(2)/day by intravenous (i.v.) bolus injection on day 1), etopo
Autor:
B Ricciardi, Michele Caraglia, A Leardi, M Graziano, Ar Bianco, Elide Matano, M DeLaurentiis, S Deplacido, Pierosandro Tagliaferri
Publikováno v:
International journal of oncology. 8(5)
We have demonstrated that interferon-alpha 2 recombinant (IFN alpha) inhibits the growth and modulates the expression of the receptor for transferrin (TRF-R) in human epidermoid carcinoma KB cells. Receptor upregulation results in the reconstitution
Autor:
M Brandi, G. Palomba, Ar Bianco, Chiara Carlomagno, M. Lopez, Lorusso, Fosser, M. D'Aprile, M Delena, Patrizia Vici, Andrea Piano, S Deplacido
Publikováno v:
International Journal of Oncology. 2:531-535
A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) admini
Autor:
C. Pagliarulo, G. Frasci, B. Ungaro, L. Bazzicalupo, Francesco Caponigro, Rosario Vincenzo Iaffaioli, S Deplacido, Ar Bianco, G. Esposito
Publikováno v:
Scopus-Elsevier
CA 15-3, TPA and CEA were assayed before surgery in 60 patients with breast cancer. A significant association was found between preoperative CA 15-3 levels and some of the most important prognostic factors in breast cancer, such as lymph node status
Publikováno v:
International Journal of Oncology.
The overview published in 1999 by the Early Breast Cancer Trialist' Cooperative Group demonstrated that systemic therapy after surgical removal of primary breast tumors prolongs both disease-free and overall survival of patients when compared with no
Autor:
A. Ruggiero, L. Panico, B Fiorentino, Stefano Pepe, Chiara Carlomagno, M Delaurentiis, Ar Bianco, Guido Pettinato, F. Perrone, S Deplacido, Gaetano Borriello, Nicola Normanno
Paraffin-embedded tissues are used in retrospective studies to evaluate the prognostic significance of DNA-flow cytometry (DNA-FCM) in human breast cancer. Although paraffin-embedded samples yield information on disease-free survival (DFS) and overal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc1ad1ded72a3e04d3dd27fbeef68a66
http://hdl.handle.net/11588/667997
http://hdl.handle.net/11588/667997
Autor:
Ciro Gallo, Rossella Lauria, L. Panico, E. Perrone, S Deplacido, Chiara Carlomagno, Guido Pettinato, Alessandro Morabito, M Delaurentiis, Ar Bianco
Publikováno v:
European Journal of Cancer. 31:S11
Aim To study retrospectively the interaction between ErbB2 overexpression and adjuvant tamoxifen in node negative breast cancer patients (pts) entered into the controlled clinical trial GUN-I (Lancet 1988, ii: 1095) Patients and Methods ErbB2 was eva
Autor:
Rossella Lauria, Graziano R, S Deplacido, Sandro Pignata, M. Pergola, Antonio Maffeo, F. Perrone, Ettore Ferrari, Alessandro Morabito, Chiara Carlomagno, G DePlacido, E Biondi, Ciro Gallo, Ar Bianco
Publikováno v:
Scopus-Elsevier
Cisplatin and carboplatin are both active in ovarian cancer with different toxicity profiles; thus, dose intensification may be possible by combining them. The aim of the present study was to determine the maximum tolerated dose of carboplatin combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b7c3cc43fa7e5ffb1ec0b9d5ed08e5
http://www.scopus.com/inward/record.url?eid=2-s2.0-12644263414&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-12644263414&partnerID=MN8TOARS
Publikováno v:
AISHE-J: The All Ireland Journal of Teaching & Learning in Higher Education; Autumn2023, Vol. 15 Issue 3, p1-14, 14p